OliX: A New Frontier in Brain Drug Delivery

South Korean biotech firm OliX has recently demonstrated the potential of a technology that allows drugs to be safely delivered to the brain via standard injections, without direct brain administration. This is based on preclinical results showing that drugs administered through intravenous (IV) or subcutaneous (SC) injections can cross the blood-brain barrier (BBB) and exert a meaningful effect in brain tissue. Such research is expected to bring significant changes to the future treatment of brain-related diseases.

Collaboration Between OliX and Vect-Horus

OliX secured this preclinical data through joint research with French biotech company Vect-Horus. This study combined OliX's gene therapy technology, siRNA, with Vect-Horus's blood-brain barrier (BBB) shuttle platform, VECTrans. The research results showed that the siRNA therapeutic agent successfully crossed the blood-brain barrier and was delivered to the central nervous system (CNS) through systemic administration methods like intravenous and subcutaneous injections.

An Innovative Approach Reducing Patient Burden

A particularly noteworthy aspect is that this technology enables drug delivery to the brain through standard injections, bypassing the need for direct brain administration. This is being hailed as an innovative approach that can reduce the burden and pain associated with drug administration for patients in future CNS therapeutic development. This method enhances treatment convenience and can offer a better experience for patients.

Future Prospects and Strategic Discussions

Through this research, OliX and Vect-Horus have early confirmed the practical feasibility of developing siRNA-based CNS therapeutics. This is expected to serve as a cornerstone for future research collaborations and strategic discussions. An OliX representative stated, "We plan to actively utilize these achievements as business development material at 2026 BIO USA to initiate substantive discussions on partnerships with potential global pharmaceutical and biotech players."

In conclusion, OliX's research findings are anticipated to be a crucial milestone in the development of treatments for brain diseases. With the establishment of a new method to cross the blood-brain barrier, the development of future therapeutics holds great promise. It is important to pay attention to OliX's continuous efforts to provide better treatment options for patients.